Clinical Trials Browser

INDUSTRY × Triple Negative Breast Neoplasms × sacituzumab govitecan × Clear all

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT06926920 2026-01-30

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05382299 2025-09-05

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT05101096 2025-03-25

ASCENT-J02

Phase 1/2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT02161679 2021-08-19

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT04320693 2021-08-19

Expanded Access for IMMU-132

Approved for marketing

Triple Negative Breast Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 2 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms